Emicizumab Improves Ex Vivo Clotting Function in Patients with Mild/Moderate Hemophilia A

Abstract

Emicizumab enhances coagulation potential in PwMHA. Assessment of <i>ex vivo</i> coagulant activity of emicizumab could be helpful for predicting coagulant potentials prior to treatment in these patients.